Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Black Diamond Therapeutics, Inc.BDTX · Entity 6669 | Director · 10% owner | June 18, 2021 | June 22, 2021 |
| CRISPR Therapeutics AGCRSP · Entity 3852 | Director | June 09, 2022 | June 10, 2022 |
| Monte Rosa Therapeutics, Inc.GLUE · Entity 4828 | Director · 10% owner | June 28, 2021 | June 30, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Black Diamond Therapeutics, Inc.
Report date June 18, 2021 · Filed June 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.55 · Expires 2031-06-17 | Direct | 15,000 |
Reported balance
After 2021-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-18 · Grant · Acquired 15,000 · Balance 15,000 F1: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2022 or (ii) the next annual meeting of the Issuer's stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2022 or (ii) the next annual meeting of the Issuer's stockholders.
CRISPR Therapeutics AG
Report date June 09, 2022 · Filed June 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.70 · Expires 2032-06-09 | Direct | 12,000 |
Reported balance
After 2022-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-09 · Grant · Acquired 12,000 · Balance 12,000 F1: This option was granted on June 9, 2022 with respect to 12,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2022; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2023 Annual General Meeting of Shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 9, 2022 with respect to 12,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2022; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2023 Annual General Meeting of Shareholders.
Monte Rosa Therapeutics, Inc.
Report date June 28, 2021 · Filed June 30, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Versant Venture Capital VI, L.P. | 6,799,115 |
Reported balance
After 2021-06-28 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-06-28 · Conversion · Acquired 6,515,869 · Balance 6,799,115 F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F2: Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Versant Vantage I, L.P. | 2,097,938 |
Last balance in matching sequence
After 2021-06-28 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 2 · 2021-06-28 · Conversion · Acquired 1,940,043 · Balance 1,940,043 F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F3: Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Row 3 · 2021-06-28 · Purchase · Acquired 157,895 · Balance 2,097,938 F3: Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. |
| Series A convertible preferred stockSEC Table II · derivative / convertible security | IndirectBy Versant Capital VI, L.P. | 0 |
Reported balance
After 2021-06-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-06-28 · Conversion · Disposed 20,004,280 · Balance 0 F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F2: Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. |
| Series B convertible preferred stockSEC Table II · derivative / convertible security | IndirectBy Versant Capital VI, L.P. | 0 |
Reported balance
After 2021-06-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-06-28 · Conversion · Disposed 3,000,000 · Balance 0 F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F2: Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. |
| Series B convertible preferred stockSEC Table II · derivative / convertible security | IndirectBy Versant Vantage I, L.P. | 0 |
Reported balance
After 2021-06-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-06-28 · Conversion · Disposed 4,150,000 · Balance 0 F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F3: Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. |
| Series C convertible preferred stockSEC Table II · derivative / convertible security | IndirectBy Versant Vantage I, L.P. | 0 |
Reported balance
After 2021-06-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-06-28 · Conversion · Disposed 2,699,328 · Balance 0 F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F3: Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.
F2: Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
F3: Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 28, 2021 Filed Jun 30, 2021 17:05 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | ConversionCommon Stock | 6,515,869 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-026769 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Versant Venture Capital VI, L.P. Disclosed balance after: 6,799,115 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 17:00 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 47,132 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-21-025978 · doc4.xml · derivative · entry 4 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,132 Underlying: Common Stock · 47,132 shares Expires 2031-06-22 F5 · derivative.exercise_date: This option shall vest in 36 substantially equal monthly installments, with the first installment vesting on June 28, 2021. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 22:12 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $12.55 | $0.00 |
DisclosureSEC source: 0001104659-21-084239 · tm2120371-1_4seq1.xml · derivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-17 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2022 or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 20:41 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 755 | $129.45 | $97,732.64 |
DisclosureSEC source: 0000899243-21-023880 · doc4.xml · nonDerivative · entry 5 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,375 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $129.37 to $129.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 20:41 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,100 | $128.65 | $141,516.98 |
DisclosureSEC source: 0000899243-21-023880 · doc4.xml · nonDerivative · entry 4 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,130 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $128.29 to $129.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 20:41 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 800 | $127.88 | $102,307.04 |
DisclosureSEC source: 0000899243-21-023880 · doc4.xml · nonDerivative · entry 3 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,230 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $127.29 to $128.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 20:41 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,918 | $126.59 | $242,808.44 |
DisclosureSEC source: 0000899243-21-023880 · doc4.xml · nonDerivative · entry 2 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,030 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $126.14 to $127.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 20:41 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 5,427 | $125.62 | $681,753.31 |
DisclosureSEC source: 0000899243-21-023880 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,948 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $125.13 to $126.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:36 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $123.71 | $0.00 |
DisclosureSEC source: 0001209191-21-040292 · doc4.xml · derivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2031-06-10 F1 · derivative.exercise_date: This option was granted on June 10, 2021 with respect to 10,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2021; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2022 Annual General Meeting of Shareholders. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 22:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 300 | $134.93 | $40,478.01 |
DisclosureSEC source: 0000899243-21-013316 · doc4.xml · nonDerivative · entry 7 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,375 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F8 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $134.88 to $135.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (8) to this Form 4. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 22:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 5,237 | $134.33 | $703,495.11 |
DisclosureSEC source: 0000899243-21-013316 · doc4.xml · nonDerivative · entry 6 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,675 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F7 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $133.87 to $134.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (7) to this Form 4. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 22:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 9,334 | $133.28 | $1,244,070.06 |
DisclosureSEC source: 0000899243-21-013316 · doc4.xml · nonDerivative · entry 5 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,912 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $132.86 to $133.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 22:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 6,090 | $132.53 | $807,092.48 |
DisclosureSEC source: 0000899243-21-013316 · doc4.xml · nonDerivative · entry 4 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,246 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $131.86 to $132.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 22:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 2,400 | $131.14 | $314,741.28 |
DisclosureSEC source: 0000899243-21-013316 · doc4.xml · nonDerivative · entry 3 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,336 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $130.75 to $131.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 22:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 3,413 | $130.42 | $445,111.86 |
DisclosureSEC source: 0000899243-21-013316 · doc4.xml · nonDerivative · entry 2 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,736 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $129.75 to $130.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 22:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 3,600 | $129.36 | $465,678.00 |
DisclosureSEC source: 0000899243-21-013316 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,149 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $128.74 to $129.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| March 11, 2021 Filed Jun 25, 2021 17:00 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantSeries C convertible preferred stock · Derivative | 2,699,328 | $2.96 | $7,999,998.39 |
DisclosureSEC source: 0000899243-21-025978 · doc4.xml · derivative · entry 3 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Versant Vantage I, L.P. Disclosed balance after: 2,699,328 Underlying: Common Stock · 764,573 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") is convertible into shares of the Issuer's Common Stock on a 3.5305-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 7. The Preferred Stock has no expiration date. F2 · kind: This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The securities covered by such transaction were previously included on the Reporting Person's Form 3. F1 · derivative.exercise_date: Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") is convertible into shares of the Issuer's Common Stock on a 3.5305-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 7. The Preferred Stock has no expiration date. F1 · derivative.expiration_date: Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") is convertible into shares of the Issuer's Common Stock on a 3.5305-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 7. The Preferred Stock has no expiration date. F4 · ownership.nature: Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:23 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 565 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009385 · doc4.xml · nonDerivative · entry 12 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,749 F18 · kind: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V CAN. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:23 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 4,012 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009385 · doc4.xml · nonDerivative · entry 11 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F17 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V CAN to its partners. F16 · ownership.nature: Shares held by VV V CAN. VV V CAN GP is the sole general partner of VV V CAN. VV V CAN GP may be deemed to have voting and dispositive power over the securities held by VV V CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the securities through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:23 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 4,012 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009385 · doc4.xml · nonDerivative · entry 10 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,012 F15 · kind: Represents a change in the form of ownership of VV V CAN by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC CAN. F16 · ownership.nature: Shares held by VV V CAN. VV V CAN GP is the sole general partner of VV V CAN. VV V CAN GP may be deemed to have voting and dispositive power over the securities held by VV V CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the securities through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:23 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 18,574 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009385 · doc4.xml · nonDerivative · entry 9 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 44,295 F13 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V (Canada) LP ("VVC CAN") to its partners pursuant to a Rule 10b5-1 trading plan. F14 · ownership.nature: These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. Each of VV V CAN GP and VV V CAN may be deemed to have voting and dispositive power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the securities through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:23 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 12,648 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009385 · doc4.xml · nonDerivative · entry 8 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,184 F12 · kind: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:23 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 56,056 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009385 · doc4.xml · nonDerivative · entry 7 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F11 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V to its members. F4 · ownership.nature: Shares held of record by VV V. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:23 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 1,755 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009385 · doc4.xml · nonDerivative · entry 6 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 56,056 F10 · kind: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VOA. F4 · ownership.nature: Shares held of record by VV V. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:23 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 8,126 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009385 · doc4.xml · nonDerivative · entry 5 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 18,457 F8 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA") to its partners pursuant to a Rule 10b5-1 trading plan. F9 · ownership.nature: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and dispositive power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:23 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 1,585 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009385 · doc4.xml · nonDerivative · entry 4 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 54,301 F7 · kind: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VAF V. F4 · ownership.nature: Shares held of record by VV V. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:23 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 7,341 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009385 · doc4.xml · nonDerivative · entry 3 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 16,625 F5 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Affiliates Fund V, L.P. ("VAF V") to its partners pursuant to a Rule 10b5-1 trading plan. F6 · ownership.nature: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and dispositive power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:23 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 52,716 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009385 · doc4.xml · nonDerivative · entry 2 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 52,716 F3 · kind: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V. F4 · ownership.nature: Shares held of record by VV V. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:23 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 244,056 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009385 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 581,999 F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V, L.P. ("VVC V") to its partners pursuant to a Rule 10b5-1 trading plan. F2 · ownership.nature: These securities are held of record by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and dispositive power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 24, 2021 Filed Jun 25, 2021 17:00 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantSeries B convertible preferred stock · Derivative | 2,075,000 | $2.00 | $4,150,000.00 |
DisclosureSEC source: 0000899243-21-025978 · doc4.xml · derivative · entry 2 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Versant Vantage I, L.P. Disclosed balance after: 4,150,000 Underlying: Common Stock · 587,735 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") is convertible into shares of the Issuer's Common Stock on a 3.5305-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 7. The Preferred Stock has no expiration date. F2 · kind: This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The securities covered by such transaction were previously included on the Reporting Person's Form 3. F1 · derivative.exercise_date: Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") is convertible into shares of the Issuer's Common Stock on a 3.5305-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 7. The Preferred Stock has no expiration date. F1 · derivative.expiration_date: Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") is convertible into shares of the Issuer's Common Stock on a 3.5305-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 7. The Preferred Stock has no expiration date. F4 · ownership.nature: Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 24, 2021 Filed Jun 25, 2021 17:00 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantSeries B convertible preferred stock · Derivative | 1,500,000 | $2.00 | $3,000,000.00 |
DisclosureSEC source: 0000899243-21-025978 · doc4.xml · derivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Versant Capital VI, L.P. Disclosed balance after: 3,000,000 Underlying: Common Stock · 424,869 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") is convertible into shares of the Issuer's Common Stock on a 3.5305-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 7. The Preferred Stock has no expiration date. F2 · kind: This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The securities covered by such transaction were previously included on the Reporting Person's Form 3. F1 · derivative.exercise_date: Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") is convertible into shares of the Issuer's Common Stock on a 3.5305-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 7. The Preferred Stock has no expiration date. F1 · derivative.expiration_date: Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") is convertible into shares of the Issuer's Common Stock on a 3.5305-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 7. The Preferred Stock has no expiration date. F3 · ownership.nature: Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 21:40 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 847 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007816 · doc4.xml · nonDerivative · entry 22 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,536 F33 · kind: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V CAN. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 21:40 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 6,018 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007816 · doc4.xml · nonDerivative · entry 21 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F32 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V CAN to its partners. F31 · ownership.nature: Shares held by VV V CAN. VV V CAN GP is the sole general partner of VV V CAN. VV V CAN GP may be deemed to have voting and dispositive power over the securities held by VV V CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the securities through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 21:40 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 6,018 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007816 · doc4.xml · nonDerivative · entry 20 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,018 F30 · kind: Represents a change in the form of ownership of VV V CAN by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC CAN. F31 · ownership.nature: Shares held by VV V CAN. VV V CAN GP is the sole general partner of VV V CAN. VV V CAN GP may be deemed to have voting and dispositive power over the securities held by VV V CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the securities through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 21:40 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 27,861 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007816 · doc4.xml · nonDerivative · entry 19 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 62,869 F28 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V (Canada) LP ("VVC CAN") to its partners. F29 · ownership.nature: These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. Each of VV V CAN GP and VV V CAN may be deemed to have voting and dispositive power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the securities through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 21:40 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 18,973 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007816 · doc4.xml · nonDerivative · entry 18 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,689 F27 · kind: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 21:40 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 84,085 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007816 · doc4.xml · nonDerivative · entry 17 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F26 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V to its members. F19 · ownership.nature: Shares held of record by VV V. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 21:40 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 2,633 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007816 · doc4.xml · nonDerivative · entry 16 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 84,085 F25 · kind: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VOA. F19 · ownership.nature: Shares held of record by VV V. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 21:40 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 12,189 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007816 · doc4.xml · nonDerivative · entry 15 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 26,583 F23 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA") to its partners. F24 · ownership.nature: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and dispositive power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 21:40 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 2,378 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007816 · doc4.xml · nonDerivative · entry 14 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 81,452 F22 · kind: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VAF V. F19 · ownership.nature: Shares held of record by VV V. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 21:40 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 11,011 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007816 · doc4.xml · nonDerivative · entry 13 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 23,966 F20 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Affiliates Fund V, L.P. ("VAF V") to its partners. F21 · ownership.nature: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and dispositive power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 21:40 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 79,074 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007816 · doc4.xml · nonDerivative · entry 12 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 79,074 F18 · kind: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V. F19 · ownership.nature: Shares held of record by VV V. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 21:40 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 366,084 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007816 · doc4.xml · nonDerivative · entry 11 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 826,055 F16 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V, L.P. ("VVC V") to its partners. F17 · ownership.nature: These securities are held of record by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and dispositive power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 21:40 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 3,650 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007816 · doc4.xml · nonDerivative · entry 10 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,272 F14 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Side Fund IV, L.P. ("VSF IV") to its partners. F15 · ownership.nature: These securities are held of record by VSF IV. VV IV is the sole general partner of VSF IV and may be deemed to have voting and dispositive power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 21:40 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 27,716 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007816 · doc4.xml · nonDerivative · entry 9 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,716 F13 · kind: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV IV. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 21:40 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 158,522 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007816 · doc4.xml · nonDerivative · entry 8 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F12 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV IV to its members. F11 · ownership.nature: Shares held of record by VV IV. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 21:40 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 158,522 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007816 · doc4.xml · nonDerivative · entry 7 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 158,522 F10 · kind: Represents a change in the form of ownership of VV IV by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC IV. F11 · ownership.nature: Shares held of record by VV IV. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 21:40 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 615,607 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007816 · doc4.xml · nonDerivative · entry 6 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 720,481 F8 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital IV, L.P. ("VVC IV") to its partners. F9 · ownership.nature: These securities are held of record by VVC IV. Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and dispositive power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 21:40 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 3,463 | $151.82 | $525,751.97 |
DisclosureSEC source: 0000899243-21-007816 · doc4.xml · nonDerivative · entry 5 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 168,831 F1 · shares: These securities are held of record by Versant Venture Management LLC ("VVM LLC"), a portion of which are held for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. F7 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $151.61 to $151.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (7) to this Form 4. F3 · ownership.nature: These securities are held of record by VVM LLC. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 21:40 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 27,932 | $150.99 | $4,217,461.06 |
DisclosureSEC source: 0000899243-21-007816 · doc4.xml · nonDerivative · entry 4 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 172,294 F1 · shares: These securities are held of record by Versant Venture Management LLC ("VVM LLC"), a portion of which are held for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $150.61 to $151.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4. F3 · ownership.nature: These securities are held of record by VVM LLC. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.